Vertebroplasty and Kyphoplasty Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Vertebroplasty and Kyphoplasty Market Size, Share & Trends Analysis Report By Device Type, By Application, By End-user, By Region, And Segment Forecasts, 2024-2031

Report Overview

Global Vertebroplasty and Kyphoplasty Market reached US$ 1.2 billion in 2023 and is expected to reach US$ 1.7 billion by 2031, growing at a CAGR of 5% during the forecast period 2024-2031.

Vertebroplasty and kyphoplasty are relatively new techniques for the treatment of pain caused by vertebral body compression fractures and stabilize the spine, thereby preventing further spinal dysfunction and improving quality of life.

Kyphoplasty differs from vertebroplasty in that a balloon is first inflated in the vertebral body to create a cavity into which cement is then injected under lower pressure. Kyphosis is a modern spine surgery procedure used to stabilize vertebral compression fractures caused by osteoporosis, cancer, and other conditions.

The market is driven by factors such as a rise in the adoption of minimally invasive surgeries, a rising incidence of osteoporosis & spinal disorders, an increase in the geriatric population, a rise in accidental cases, and technological advancements in healthcare.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Rising Incidence of Osteoporosis & Spinal Disorders

The demand for the global vertebroplasty and kyphoplasty market is driven by multiple factors. Osteoporosis is a widespread public health problem in the United States. The surgeon general of the United States has recently introduced special attention to the importance of osteoporosis to Americans extensive study states that vertebral body compression fractures are among the most common complications of osteoporosis.

 The lifetime risk of osteoporotic spine fracture in white women is 15.6%. Each year, more than 700,000 vertebral body fractures secondary to osteoporosis are diagnosed in the United States, resulting in 115,000 hospital admissions. The major consequences of osteoporotic compression fractures are back pain, kyphosis, and height loss.

Moreover, major key players in the industry launching new products and technology would propel this market growth. For instance, in October 2023, Amber Implants, a Netherlands-based company developing next-gen implants for spinal injuries, began clinical trials for its VCFix spinal system. The implant seeks to optimize load distribution in the spine via pedicle anchorage.

The first-in-human trial will evaluate VCFix’s safety and efficacy for patients with vertebral compression fractures. It’s also included with a single-use, sterile surgical kit to ensure traceability and reduce infection risk.

Also, in August 2021, IZI Medical officially launched Vertefix HV Cement, a product which aims to address the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures. 

Restraints

Factors such as the high cost associated with the treatment, stringent regulatory framework, complications associated with the procedures, lack of skilled professionals, and limited reimbursement policies are expected to hamper the market.

Market Segment Analysis

The global vertebroplasty and kyphoplasty market is segmented based on device type, application, end-user, and region.

The kyphoplasty device segment accounted for approximately 62.5% of the  global vertebroplasty and kyphoplasty market share

The kyphoplasty segment is expected to hold the largest market share over the forecast period. owing to the advantages that kyphoplasty provides over vertebroplasty, such as reduction in back pain, as well as restoration of vertebral body height, and a lower rate of cement extravasation. This is mainly done by placing balloons to gently elevate the fractured vertebrae in an attempt to return them to the correct position. 

According to the study published in Frontiers in Surgery Journal in July 2022, the use of kyphoplasty for the clinical treatment of osteoporotic vertebral compression fractures, spinal metastatic tumors, hemangiomas, myelomas, and vertebral nonunion has increased with the global development of minimally invasive spinal surgery. 

Therefore, the rising adoption of kyphoplasty procedures for the treatment of vertebral compression fractures and cancers will lead to increased adoption of kyphoplasty devices, expected to drive the segment's growth.

Market Geographical Share

North America accounted for approximately 42.3% of the global vertebroplasty and kyphoplasty market share 

North America region is expected to hold the largest market share over the forecast period owing to factors such as better healthcare infrastructure, rising funding from the government, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the region.

For instance, in September 2022, RevBio was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health. With the help of this grant, the company will be able to develop Tetranite, a patented bone adhesive technology, for the treatment of vertebral compression fractures. 

Therefore, such funding for the development of technologies in vertebral compression fractures is expected to drive market growth due to the increased launch and adoption of products in the market over the forecast period.

Furthermore, according to Osteoporosis Canada, 2022, more than 2.3 million Canadians are living with osteoporosis and at least 1 in 3 women and 1 in 5 men suffer from an osteoporotic fracture during their lifetime. Such a huge prevalence of osteoporosis in Canada is expected to increase the adoption of vertebroplasty and kyphoplasty procedures in the Canadian population, thereby leading to the rising adoption of vertebroplasty and kyphoplasty devices, driving the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global vertebroplasty and kyphoplasty market. Hospital admissions for patients other than COVID-19 and serious diseases were restricted to hospitals to avoid the spread of the virus. 

For instance, according to the study published in SAGE Journals in April 2022, there have been noticeable changes in the hospital admissions of patients with vertebral compression fractures (VCF) compared to the period before the COVID-19 pandemic. Fewer patients visited the emergency department for VCF during the peak of the Covid-19 pandemic which represented a 44% decrease. Hence, COVID-19 affected the pace of the market at the beginning of the pandemic.

Market Segmentation

By Device Type

• Vertebroplasty Device

• Needle
• Cement Mixing & Delivery Devices
• X-ray Device

•  Kyphoplasty Device

• Needle
•  Balloon
• X-ray Device

By Application

• Traumatic Vertebral Fractures
• Osteoporotic Vertebral Fractures

By End-User

• Hospitals
• Ambulatory Surgical Centers
• Others

By Region

• North America 
• U.S.
• Canada
• Mexico 
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Rest of Europe 
• South America
• Brazil
• Argentina
• Rest of South America 
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the vertebroplasty and kyphoplasty market include Medtronic, Jayon Implants, Johnson & Johnson, Joimax, Teknimed, Globus Medical, Stryker, MEDAID Inc, Biopsybell, and Merit Medical Systems among others.

Key Developments

• In August 2023, Safe Orthopaedics SAS reported results from a biomechanical study comparing its new surgical technique Sycamore a pedicle-anchored implant with standalone balloon kyphoplasty.
• In October 2022, Halma announced the acquisition of IZI Medical Products, a leading designer, manufacturer, and distributor of medical devices used across a range of diagnostic and therapeutic procedures. IZI Medical Products offers vertebroplasty and kyphoplasty products such as DURO-JECT Bone Cement Injector Set, Vertefix HV High Viscosity Bone Cement, and Kiva VCF Treatment System, which further expands Halma’s product portfolio. 
• In April 2022, Nanox announced FDA approval for HealthOST Device, an AI software monitoring vertebral compression fractures and low bone density, which are frequently associated with osteoporosis.
• In February 2022, Enlife Solutions represented Tecres, an Italian company in Romania. The representation includes a spinal and cranial portfolio of Tecres, including a Mendec spine vertebroplasty kit for osteoporosis.

Why Purchase the Report?

• To visualize the global vertebroplasty and kyphoplasty market segmentation based on device type, application, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global vertebroplasty and kyphoplasty market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global vertebroplasty and kyphoplasty market report would provide approximately 62 tables, 55 figures, and 182 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies